Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06325774 | Radical Hypofractionated Radiotherapy for Localized Prostate Cancer | recruiting | N/A | 20 | Changhai HospitalOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06325995 | Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer | recruiting | N/A | 428 | Changhai HospitalOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT01970696 |
| International Ovarian & Testicular Stromal Tumor Registry(OTST) |
| recruiting |
| — |
| 300 |
| Children's Hospitals and Clinics of MinnesotaOTHER |
| 1 |
| Aug 22, 2024 |
| clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03360994 | WATChmAN Virtual Testicular Cancer Clinic | active not recruiting | N/A | 144 | University Health Network, TorontoOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05478876 | Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract(CYCLE) | recruiting | N/A | 9 | CNAO National Center of Oncological HadrontherapyOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05472311 | Cervical Cancer Elimination -Using Implementation Science to Evaluate Deliver and Cost Introduction of Thermal Ablation(TIBA) | recruiting | N/A | 565 | University of WashingtonOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06524219 | Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery. | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 19, 2024 | clinicaltrials |
| NCT06557954 | Cervical Cytology DNA Methylation for Cervical Cancer Screening | not yet recruiting | — | 30,000 | Lei LiOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06556342 | The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women | recruiting | N/A | 198 | Tongji HospitalOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06558019 | Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence | not yet recruiting | — | 509 | Lei LiOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06362577 | Clinical Study of HIFU for Localized Prostate Cancer(HIFU) | recruiting | — | 60 | RenJi HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06343038 | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study(PROGNOSTICS) | recruiting | Phase 1 | 25 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06394492 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 440 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546527 | Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） | not yet recruiting | Early Phase 1 | 12 | Peking University First HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06541171 | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results(FOFU) | not yet recruiting | — | 220 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06541288 | A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer | not yet recruiting | N/A | 230 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT06529549 | Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment | recruiting | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05764044 | Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer(AddChemo) | recruiting | Phase 3 | 365 | Hospital do CoracaoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06528236 | Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass | not yet recruiting | — | 100,000 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06509724 | Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy(POHIM-P3) | recruiting | Phase 3 | 248 | Samsung Medical CenterOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06518226 | Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer(TURBO) | recruiting | N/A | 160 | UMC UtrechtOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06283875 | The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | not yet recruiting | — | 80 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06501417 | EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome(EC_ItaLynch) | not yet recruiting | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06501846 | Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.(PUG) | recruiting | N/A | 92 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06494696 | 68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk | recruiting | — | 71 | Chang Gung Memorial HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03386734 | International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer(SENTICOLIII) | active not recruiting | N/A | 989 | Centre Hospitalier Universitaire de BesanconOTHER | 14 | Jul 8, 2024 | clinicaltrials |
| NCT06489496 | Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial(PAX) | not yet recruiting | — | 1,000 | Alberta Health servicesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT06491056 | Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)(ProAMFocal) | recruiting | — | 500 | Singapore General HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05549024 | 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients | recruiting | Early Phase 1 | 90 | Peking Union Medical College HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04807166 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | active not recruiting | Phase 2 | 56 | Wenjun ChengOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05352178 | Metastasis-directed Therapy for Oligorecurrent Prostate Cancer(SPARKLE) | recruiting | Phase 3 | 873 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483425 | A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer | active not recruiting | — | 2,000 | Tongji HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05410717 | CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors | recruiting | Phase 1 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04295447 | Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy(ADAM) | active not recruiting | Phase 2 | 190 | Universität MünsterOTHER | 2 | Jun 20, 2024 | clinicaltrials |
| NCT06462378 | Proton Therapy for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 55 | University of AarhusOTHER | 1 | Jun 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2024source: clinicaltrials